AlmirallShare, the open innovation platform of Almirall, S.A. (ALM) launches today an open call with the aim of finding advanced small molecules that could be used in the treatment of atopic dermatitis, psoriasis, acne, actinic keratosis, and related dermatological diseases. The call is addressed to universities, research centers, biotech companies, start-ups, and pharma companies all over the world with an interest in pharmaceutical R&D.
More specifically, this call is looking for Research compounds that have shown good potency and an acceptable pharmacokinetic profile or Development compounds that have shown a good human safety profile.
Submitting a proposal is as easy as going to sharedinnovation.almirall.com and following the steps described at the collaboration process. The call will be open permanently, so applicants can participate at any time. The evaluation period of each proposal will take 4-6 weeks from submission.
Selected compounds will be tested on key dermatological assays both in vitro and in vivo. “Those compounds that show interesting biological profiles would give us the opportunity for an eventual business partnership. Our aim is to build fruitful collaborations that will lead us to future exciting ventures” said Maribel Crespo, AlmirallShare Leader.
For more information, please visit almirall.com.